Actinium Pharmaceuticals, a clinical-stage biopharmaceutical company based in New York (USA) entered into a research and option agreement with Astellas Pharma to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology.
Actinium Pharmaceuticals focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.
Under this collaboration, Actinium will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with the powerful actinium-225 (225Ac) payload. Actinium will also be responsible for conducting preclinical validation studies on the novel ARCs generated.
Actinium formally launched its AWE Program in November 2017 at its centerpiece the AWE Platform Technology. The Company’s proprietary AWE Platform Technology is supported by intellectual property and know-how that enables the creation of Actinium-225 (225Ac) Radio-Conjugates (ARCs) wherein a biomolecular targeting agent is stably labeled with the powerful 225Ac payload to enhance targeted cell killing.
The AWE Program is structured to provide the opportunity for partners or collaborators to derive maximum value from a collaboration by leveraging Actinium’s extensive technical know-how, access to its ARC drug development infrastructure and to its underlying AWE Platform Technology. The AWE Program provides a partner or collaborator with access to Actinium’s knowledge bank and infrastructure allowing collaborators to benefit from accelerated development timelines for its ARCs.